Author:
Mali Aniket,Sawant Apurva,Mahadik Anagha,Nair Sujit
Reference137 articles.
1. Agius M, Klodowska-Duda G, Maciejowski M, Potemkowski A, Sweeny S, Li J et al (2015) Safety and tolerability of MEDI-551 in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler 23(11):235–236
2. Al Sawah S, Foster SA, Goldblum OM, Malatestinic WN, Zhu B, Shi N et al (2017) Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ 20(9):982–990
3. Anandarajah AP, Luc M, Ritchlin CT (2017) Hospitalization of patients with systemic lupus erythematosus is a major cause of direct and indirect healthcare costs. Lupus 26(7):756–761
4. Astrakhantseva IV, Efimov GA, Drutskaya MS, Kruglov AANS (2014) Modern anti-cytokine therapy of autoimmune diseases. Biochemist 79(12):1308–1321
5. Augustin M, Vietri J, Tian H, Gilloteau I (2017) Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. J Eur Acad Dermatol Venereol 31(8):1316–1323